A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab...

Blood Advances 2020 / 04 Vol. 4; Iss. 8

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Lancet, Jeffrey E., Moseley, Anna B., Coutre, Steven E., DeAngelo, Daniel J., Othus, Megan, Tallman, Martin S., Litzow, Mark R., Komrokji, Rami S., Erba, Harry P., Appelbaum, Frederick R.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
4
Journal:
Blood Advances
DOI:
10.1182/bloodadvances.2019001278
Date:
April, 2020
File:
PDF, 934 KB
2020
Conversion to is in progress
Conversion to is failed